AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact - Pharmaceutical Technology

Summit is currently developing Ivonescimab in combination with other drugs across several types of solid tumours. Ivonescimab is currently in development as a combination drug across several types of solid tumours. Ivonescimab is currently in clinical trials for several solid tumour types. Credit: ivector / Shutterstock.com. AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), alongside Summit’s in-licensed candidate, ivonescimab. Through this collaboration, AstraZeneca and Daiichi will sponsor a range of trials evaluating the effectiveness of Datroway and the PD-1 × VEGF-targeting bispecific antibody, ivonescimab, in several…

Source: Pharmaceutical Technology